WASHINGTON (AP) — OxyContin maker Purdue Pharma shouldn't give its CEO a bonus next year as the company goes through bankruptcy and tries to settle 2,700 lawsuits over the opioid crisis, 11 U.S. senators said in a letter Tuesday.
A bankruptcy judge approved the company's plan to award bonuses to other employees earlier this month, but delayed a decision on whether CEO Craig Landau should receive an expected $1.3 million next year. That amount would be on top of his $2.6 million base salary. Under pressure from states and others, the company cut Landau's proposed bonus in half.
"Purdue is still more concerned with motivating high-level employees to sell more drugs than it is with public health or helping states ravished by the opioid crisis," the senators wrote in the letter.
A Purdue
